TCGA data analysis revealed that C16orf54 expression was substantially upregulated in glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), and kidney renal clear cell carcinoma (KIRC), whereas it was downregulated in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma (READ), lung adenocarcinoma (LUAD), uterine corpus endometrial carcinoma (UCEC), and thyroid carcinoma (THCA) compared to the corresponding samples from normal tissues (Figure 1(c)). Here, C16orf54 is linked to invasive breast carcinoma.